0000000000344025

AUTHOR

Giuseppe Vitale

showing 12 related works from this author

Comparison of Ivabradine Versus Metoprolol in Early Phases of Reperfused Anterior Myocardial Infarction With Impaired Left Ventricular Function: Prel…

2009

BACKGROUND: beta-blockers in ST-segment elevation myocardial infarction (STEMI) are indicated for patients without a contraindication, particularly in patients with high heart rates (HR) or blood pressures. Epidemiological studies have shown that elevated HR represents a risk factor for cardiovascular morbidity. The study investigates the feasibility, tolerability, and the effects after 30 days of follow-up of ivabradine (IVA) versus metoprolol (METO) in early phases of anterior STEMI reperfused by percutaneous coronary intervention (PCI). METHODS AND RESULTS: Patients with a first anterior STEMI, Killip class I-II, an acceptable echocardiographic window, and admitted within 4hours of the o…

Malemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentMyocardial InfarctionMyocardial Reperfusion InjuryPilot ProjectsVentricular Dysfunction LeftDouble-Blind MethodInternal medicineejection fraction end systole volume ivabradinemedicineHumansIvabradinecardiovascular diseasesMyocardial infarctionAgedMetoprololKillip classEjection fractionbusiness.industryPercutaneous coronary interventionBenzazepinesMiddle Agedmedicine.diseasesurgical procedures operativeConventional PCICardiologyMyocardial infarction complicationsFemaleCardiology and Cardiovascular MedicinebusinessIvabradineFollow-Up StudiesMetoprololmedicine.drugJournal of Cardiac Failure
researchProduct

The Effects of Sacubitril/Valsartan on Clinical, Biochemical and Echocardiographic Parameters in Patients with Heart Failure with Reduced Ejection Fr…

2019

Background: Sacubitril/valsartan has been shown to be superior to enalapril in reducing the risks of death and hospitalization for heart failure (HF). However, knowledge of the impact on cardiac performance remains limited. We sought to evaluate the effects of sacubitril/valsartan on clinical, biochemical and echocardiographic parameters in patients with heart failure and reduced ejection fraction (HFrEF). Methods: Sacubitril/valsartan was administered to 205 HFrEF patients. Results: Among 230 patients (mean age 59 &plusmn

medicine.medical_specialtymedicine.medical_treatmentheart failureHemodynamics030204 cardiovascular system & hematologyArticleSacubitril03 medical and health sciences0302 clinical medicinehemodynamicInternal medicinemedicineechocardiography030212 general & internal medicineEnalaprilremodelingEjection fractionbusiness.industryneprilysin inhibitionGeneral Medicinemedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareValsartansacubitril/valsartanHeart failureCardiologyreduced ejection fractionDiureticbusinessNt-ProBNPSacubitril Valsartanmedicine.drugJournal of Clinical Medicine
researchProduct

Combination of indomethacin and statin compared with indomethacin and placebo in patients with a first episode of acute pericarditis: preliminary fin…

2007

The aim of the present study was to evaluate the safety and efficacy of the combination of indomethacin and statin compared with indomethacin plus placebo in patients with a first episode of pericarditis. A total of 55 consecutive patients with acute pericarditis were randomized in a double-blind manner into two groups: group I (statin group) was treated with 150 mg of indomethacin plus 10 mg of rosuvastatin, and group 2 (placebo group) was treated with 150 mg of indomethacin plus placebo. Both groups received treatment up to the normalization of inflammation markers and for the following week. Clinical and laboratory assessments [white cell count, ESR (erythrocyte sedimentation rate) and C…

AdultMalemedicine.medical_specialtyIndomethacinPlaceboGastroenterologyElectrocardiographyPericarditisAcute pericarditisDouble-Blind MethodRecurrenceInternal medicineTroponin ImedicineHumansPericarditisRosuvastatinRosuvastatin CalciumPericarditis Colchicine Postpericardiotomy syndromeFirst episodeSulfonamidesmedicine.diagnostic_testbiologybusiness.industryAnti-Inflammatory Agents Non-SteroidalCardiovascular AgentsGeneral Medicinemedicine.diseaseSurgeryFluorobenzenesC-Reactive ProteinPyrimidinesTreatment OutcomeErythrocyte sedimentation rateAcute Diseasebiology.proteinDrug Therapy CombinationFemaleCreatine kinaseHydroxymethylglutaryl-CoA Reductase InhibitorsInflammation MediatorsbusinessFollow-Up Studiesmedicine.drugClinical Science
researchProduct

A new eco-friendly chemical treatment of natural fibres: Effect of sodium bicarbonate on properties of sisal fibre and its epoxy composites

2016

Abstract Several researchers have shown how sisal fibres possess remarkable tensile properties that yield them good candidates as reinforcement in biocomposite materials. This work aims to evaluate the effect of an eco-friendly and cost effective surface treatment method based on the use of commercial sodium bicarbonate (i.e. baking soda) on properties of sisal fibre and its epoxy composites. In particular, raw sisal fibres were treated with a 10%w/w of sodium bicarbonate solution for different periods (24, 120 and 240 h), at room temperature. Changes occurring in sisal fibres were characterized through scanning electron microscope, Fourier transform infrared spectroscopy, thermogravimetric…

Thermogravimetric analysisMaterials scienceScanning electron microscopeB. Mechanical propertie02 engineering and technology010402 general chemistry01 natural sciencesIndustrial and Manufacturing EngineeringFibreFlexural strengthUltimate tensile strengthThermal analysisComposite materialFourier transform infrared spectroscopySISALcomputer.programming_languageStatistical properties/methodMechanical EngineeringEpoxyChemical treatment021001 nanoscience & nanotechnology0104 chemical sciencesSettore ING-IND/22 - Scienza E Tecnologia Dei MaterialiMechanics of Materialsvisual_artCeramics and Compositesvisual_art.visual_art_mediumBiocomposite0210 nano-technologycomputerA. Fibres; B. Mechanical properties; C. Statistical properties/methods; Chemical treatment; D. Thermal analysis; Ceramics and Composites; Mechanics of Materials; Mechanical Engineering; Industrial and Manufacturing Engineering
researchProduct

Is delayed facilitated percutaneous coronary intervention better than immediate in reperfused myocardial infarction? Six months follow up findings

2006

Background: There are several new strategies proposed to improve the outcome of patients with ST-elevation myocardial infarction (STEMI). One approach is the resurgent use of facilitated percutaneous coronary interventions (PCI). Until recently, deciding whether immediate PCI after combined treatment (facilitated PCI) is more appropriate than delayed PCI (short time) has not been investigated. The aim of this study, therefore, was to investigate the outcomes in patients initially successfully treated pharmacologically and immediate PCI < 2 hr, and in patients initially successfully treated with pharmacological therapy and with delayed PCI (12–72 h). Methods: 451 reperfused STEMI patients, a…

Malemedicine.medical_specialtyTiclopidineTime Factorsmedicine.medical_treatmentMyocardial InfarctionFacilitated Percutaneous Coronary InterventionPlatelet Glycoprotein GPIIb-IIIa ComplexGIIb/IIIa inhibitorDelayed Percutaneous Coronary InterventionsInternal medicineAngioplastymedicineAbciximabAcute myocardial InfarctionHumanscardiovascular diseasesMyocardial infarctionAngioplasty Balloon CoronaryAgedbusiness.industryAnticoagulantsPercutaneous coronary interventionHematologyTirofibanMiddle AgedClopidogrelmedicine.diseaseCombined Modality TherapyClopidogrelsurgical procedures operativeTissue Plasminogen ActivatorConventional PCICardiologyFemaleCardiology and Cardiovascular MedicinebusinesstherapeuticsCombined therapyPlatelet Aggregation InhibitorsTIMIFollow-Up Studiesmedicine.drugJournal of Thrombosis and Thrombolysis
researchProduct

The mutual relationship between heart failure and atrial fibrillation

2020

Atrial fibrillation (AF) and heart failure (HF) are evolving epidemies, together responsible for substantial human suffering and health-care expenditure. The simultaneous co-hexistence of the two conditions is associated with mortality rates higher than those observed in individuals with only one or none of them. Patients with concomitant HF and AF suffer from even worse symptoms and poorer prognosis, yet evidence-based evaluation and management of this group of patients is lacking. In this review, we evaluate the common mechanisms for the development of AF in HF patients and vice versa, focusing on the evidence for potential treatment strategies. Recent data have suggested that these patie…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyAdverse outcomesbusiness.industryMortality ratelcsh:Rheart failurelcsh:MedicineAtrial fibrillationArrhythmia-induced cardiomyopathymedicine.diseaseAtrial fibrillationHeart failure.Risk FactorsHeart failureConcomitantmedicineHumansTreatment strategyBest evidenceCardiology and Cardiovascular MedicineIntensive care medicinebusinessHealthcare system
researchProduct

Prognostic Value of the 6-Min Walk Test After Open-Heart Valve Surgery: EXPERIENCE OF A CARDIOVASCULAR REHABILITATION PROGRAM

2018

PURPOSE: This single-center retrospective analysis aimed to evaluate the prognostic relevance of 6-min walk test (6MWT) in patients admitted to an in-hospital cardiovascular rehabilitation program after open-heart valve surgery. METHODS: One hundred one patients able to perform a 6MWT within the first week of admission (time after surgery: 16 ± 8 d) were included (age 68 ± 11 y; 55% female; median left ventricular ejection fraction 55% [interquartile range: 50-60]; 51% after aortic valve surgery). Study endpoints were cardiovascular death and the combined outcome of cardiovascular death/cardiac hospitalization. Univariate and multivariate analyses were performed to analyze predictive value …

Pulmonary and Respiratory MedicineMalemedicine.medical_specialtyHeart Valve DiseasesWalk Test030204 cardiovascular system & hematologyPatient Readmission03 medical and health sciences0302 clinical medicineInterquartile rangePredictive Value of TestsInternal medicineNatriuretic Peptide BrainmedicineHumans030212 general & internal medicineCardiac Surgical ProceduresSurvival rateAgedRetrospective StudiesEjection fractionCardiac Rehabilitationbusiness.industryRehabilitationHazard ratioRetrospective cohort studyStroke VolumeStroke volumeLength of StayMiddle AgedBrain natriuretic peptidePrognosisPeptide FragmentsSurvival RateROC CurvePredictive value of testsArea Under CurveCardiologyFemaleCardiology and Cardiovascular MedicinebusinessFollow-Up Studies
researchProduct

Static and dynamic mechanical properties of Arundo Donax fillers-epoxy composites

2014

Abstract Aim of this work is to investigate the feasibility of using a natural and inexpensive filler obtained by grinding the culms of Arundo Donax as reinforcement of epoxy resins. The effect of the content and size of Arundo Donax fillers on static and dynamic mechanical properties was evaluated showing that the composites exhibit higher tensile moduli, comparable flexural moduli and lower strength properties in comparison to the neat resin. Moreover, changes in the storage and the loss moduli only above the glass transition temperature (i.e. in the rubbery region) were found while neither significant shifts of tan δ peaks to higher temperatures nor reductions in the peak height of the c…

Materials sciencebiologyArundo Donax fillers Epoxy composites Static properties Dynamic mechanical analysisScanning electron microscope Void contentArundo donaxDynamic mechanical analysisEpoxyengineering.materialbiology.organism_classificationSettore ING-IND/22 - Scienza E Tecnologia Dei MaterialiFlexural strengthFiller (materials)visual_artVoid (composites)Ultimate tensile strengthengineeringvisual_art.visual_art_mediumComposite materialGlass transitionMaterials &amp; Design
researchProduct

Early Effects of Sacubitril/Valsartan on Exercise Tolerance in Patients with Heart Failure with Reduced Ejection Fraction.

2019

Background. Sacubitril/valsartan in heart failure (HF) with reduced ejection fraction (HFrEF) was shown to be superior to enalapril in reducing the risk of death and hospitalization for HF. Our aim was to evaluate the cardiopulmonary effects of sacubitril/valsartan in patients with HFrEF. Methods. We conducted an observational study. Ninety-nine ambulatory patients with HFrEF underwent serial cardiopulmonary exercise tests (CPET) after initiation of sacubitril/valsartan in addition to recommended therapy. Results. At baseline, 37% of patients had New York Heart Association (NYHA) class III. After a median follow-up of 6.2 months (range 3&ndash

medicine.medical_specialtyOxygen pulselcsh:Medicineheart failure030204 cardiovascular system & hematologyArticleSacubitril03 medical and health sciences0302 clinical medicineInternal medicinemedicine030212 general & internal medicineEjection fractionbusiness.industrylcsh:RGeneral Medicinemedicine.diseaseBlood pressureValsartanHeart failuresacubitril/valsartanCardiologyexercise tolerancebusinessAnaerobic exerciseSacubitril Valsartanmedicine.drugcardiopulmonary test
researchProduct

Sacubitril/Valsartan Improves Autonomic Function and Cardiopulmonary Parameters in Patients with Heart Failure with Reduced Ejection Fraction

2020

Background: Heart rate recovery (HRR) is a marker of vagal tone, which is a powerful predictor of mortality in patients with cardiovascular disease. Sacubitril/valsartan (S/V) is a treatment for heart failure with reduced ejection fraction (HFrEF), which impressively impacts cardiovascular outcome. This study aims at evaluating the effects of S/V on HRR and its correlation with cardiopulmonary indexes in HFrEF patients. Methods: Patients with HFrEF admitted to outpatients&rsquo

medicine.medical_specialtyStress testingheart failurelcsh:Medicinecardiopulmonary exercise stress testing030204 cardiovascular system & hematologyArticleSacubitril03 medical and health sciencessacubitril/valsartan heart failure heart rate recovery peak oxygen consumption autonomic function cardiopulmonary exercise stress testing0302 clinical medicineInternal medicineHeart ratemedicine030212 general & internal medicinepeak oxygen consumptionheart rate recoveryEjection fractionbusiness.industrylcsh:RGeneral Medicinemedicine.diseaseValsartansacubitril/valsartanHeart failureBreathingCardiologyautonomic functionbusinesshuman activitiesSacubitril Valsartanmedicine.drugJournal of Clinical Medicine
researchProduct

Nemaline myopathy and heart failure: role of ivabradine; a case report

2015

Background Nemaline myopathy (NM) is a rare congenital myopathy characterized by muscle weakness, hypotonia and the presence in muscle fibers of inclusions known as nemaline bodies and a wide spectrum of clinical phenotypes, ranging from severe forms with neonatal onset to asymptomatic forms. The adult-onset form is heterogeneous in terms of clinical presentation and disease progression. Cardiac involvement occurs in the minority of cases and little is known about medical management in this subgroup of NM patients. We report a rare case of heart failure (HF) in a patient with adult-onset NM in whom ivabradine proved to be able to dramatically improve the clinical picture. Case presentation …

AdultMalemedicine.medical_specialtymedicine.medical_treatmentDilated cardiomyopathyCase ReportMyopathies NemalineElectrocardiographyNemaline myopathyInternal medicinemedicineHumansIvabradineCarvedilolNemaline myopathyHeart FailureEjection fractionbusiness.industryDilated cardiomyopathyCardiovascular AgentsBenzazepinesmedicine.diseaseImplantable cardioverter-defibrillatorCongenital myopathyTreatment OutcomeEchocardiographyHeart failureCardiologybusinessCardiology and Cardiovascular MedicineIvabradinemedicine.drugBMC Cardiovascular Disorders
researchProduct

Chemotherapy cardiotoxicity: cardioprotective drugs and early identification of cardiac dysfunction.

2016

Background: Chemotherapy cardiotoxicity is an emerging problem and it is very important to prevent cardiac dysfunction caused by anticancer drugs. The aim of this study was to assess the alterations of the cardiac function induced by chemotherapy in a follow-up of 2 years and to evaluate the cardioprotective role of angiotensin-converting enzyme inhibitors (ACEIs) in the prevention of cardiac dysfunction. Methods: A prospective study was carried out using patients with breast cancer (85 women; median age 57W12years) and other inclusion and exclusion criteria. On the basis of treatment, patients were divided into six groups: fluorouracil-epirubicincyclophosphamide, FEC (group A); FEC and tra…

Cardiac function curveAdultmedicine.medical_specialtyCardiotonic Agentsmedicine.medical_treatmentAngiotensin-Converting Enzyme InhibitorsBreast Neoplasms030204 cardiovascular system & hematologyBioinformaticsCardiac dysfunctionAngiotensin-converting enzyme inhibitor; Cardiotoxicity; Chemotherapy; Prevention; Tissue Doppler imaging; Adult; Aged; Aged 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiotonic Agents; Cardiotoxicity; Early Diagnosis; Echocardiography Doppler; Female; Follow-Up Studies; Humans; Middle Aged; Prospective Studies03 medical and health sciencesTissue Doppler imaging0302 clinical medicinecardiac toxicity anti cancer drugs cardiac dysfunctionInternal medicineAntineoplastic Combined Chemotherapy Protocols80 and overMedicineChemotherapyHumansProspective StudiesAgedAged 80 and overCardiotoxicityChemotherapybusiness.industryPreventionFollow up studiesDopplerGeneral MedicineMiddle AgedCardiotoxicityEchocardiography DopplerClinical trialEarly DiagnosisAngiotensin-converting enzyme inhibitorEchocardiography030220 oncology & carcinogenesiscardiovascular systemCardiologyFemaleCardiology and Cardiovascular MedicinebusinessFollow-Up StudiesJournal of cardiovascular medicine (Hagerstown, Md.)
researchProduct